Top

American Journal of Cardiovascular Drugs

Published in:

01-06-2016 | Current Opinion

How May Proton Pump Inhibitors Impair Cardiovascular Health?

Authors: Roman A. Sukhovershin, John P. Cooke

Published in: American Journal of Cardiovascular Drugs | Issue 3/2016

Abstract

Proton pump inhibitors (PPIs) are among the most widely used drugs worldwide. They are used to treat a number of gastroesophageal disorders and are usually prescribed as a long-term medication or even taken without a prescription. There are a number of clinical studies that associate PPI use with an increased cardiovascular risk. In this article, we review the clinical evidence for adverse cardiovascular effects of PPIs, and we discuss possible biological mechanisms by which PPIs can impair cardiovascular health.

Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? Cleveland Clin J Med. 2011;78(1):39–49. doi:10.3949/ccjm.77a.10087.CrossRef

Katz MH. Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med. 2010;170(9):747–8. doi:10.1001/archinternmed.2010.64.CrossRefPubMed

Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64(10):935–51. doi:10.1007/s00228-008-0538-y.CrossRefPubMed

Chubineh S, Birk J. Proton pump inhibitors: the good, the bad, and the unwanted. South Med J. 2012;105(11):613–8. doi:10.1097/SMJ.0b013e31826efbea.CrossRefPubMed

Eid SM, Boueiz A, Paranji S, Mativo C, Landis R, Abougergi MS. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med (Tokyo, Japan). 2010;49(23):2561–8.CrossRef

Mazer-Amirshahi M, Mullins PM, van den Anker J, Meltzer A, Pines JM. Rising rates of proton pump inhibitor prescribing in US emergency departments. Am J Emerg Med. 2014;32(6):618–22. doi:10.1016/j.ajem.2014.03.019.CrossRefPubMed

Linsky A, Hermos JA, Lawler EV, Rudolph JL. Proton pump inhibitor discontinuation in long-term care. J Am Geriatr Soc. 2011;59(9):1658–64. doi:10.1111/j.1532-5415.2011.03545.x.CrossRefPubMed

Der G. An overview of proton pump inhibitors. Gastroenterol Nursing Off J Soc Gastroenterol Nurses Assoc. 2003;26(5):182–90.CrossRef

Shin JM, Munson K, Vagin O, Sachs G. The gastric HK-ATPase: structure, function, and inhibition. Pflugers Arch. 2009;457(3):609–22. doi:10.1007/s00424-008-0495-4.CrossRefPubMedPubMedCentral

10.

Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. Best Pract Res Clin Gastroenterol. 2001;15(3):355–70. doi:10.1053/bega.2001.0184.CrossRefPubMed

11.

Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19(1):25–35. doi:10.5056/jnm.2013.19.1.25.CrossRefPubMedPubMedCentral

12.

Lindberg P, Nordberg P, Alminger T, Brandstrom A, Wallmark B. The mechanism of action of the gastric acid secretion inhibitor omeprazole. J Med Chem. 1986;29(8):1327–9.CrossRefPubMed

13.

Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc. 2004;126(25):7800–11. doi:10.1021/ja049607w.CrossRefPubMed

14.

Marino ML, Fais S, Djavaheri-Mergny M, Villa A, Meschini S, Lozupone F, et al. Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death Dis. 2010;1:e87. doi:10.1038/cddis.2010.67.CrossRefPubMedPubMedCentral

15.

Liu W, Baker SS, Trinidad J, Burlingame AL, Baker RD, Forte JG, et al. Inhibition of lysosomal enzyme activities by proton pump inhibitors. J Gastroenterol. 2013;48(12):1343–52. doi:10.1007/s00535-013-0774-5.CrossRefPubMed

16.

Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63(24):2739–54.CrossRefPubMed

17.

Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther. 2006;44(7):297–302.CrossRefPubMed

18.

Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005;20(3):153–67.CrossRefPubMed

19.

Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet. 2000;38(3):243–70. doi:10.2165/00003088-200038030-00004.CrossRefPubMed

20.

Larsson H, Mattson H, Sundell G, Carlsson E. Animal pharmacodynamics of omeprazole. A survey of its pharmacological properties in vivo. Scand J Gastroenterol Suppl. 1985;108:23–35.PubMed

21.

Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion. 2001;64(4):205–13 (48863).CrossRefPubMed

22.

Waldum HL, Qvigstad G, Fossmark R, Kleveland PM, Sandvik AK. Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scand J Gastroenterol. 2010;45(4):389–94. doi:10.3109/00365520903477348.CrossRefPubMed

23.

Choudhry U, Boyce HW Jr, Coppola D. Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol. 1998;110(5):615–21.CrossRefPubMed

24.

Hodgson N, Koniaris LG, Livingstone AS, Franceschi D. Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc. 2005;19(12):1610–2. doi:10.1007/s00464-005-0232-4.CrossRefPubMed

25.

Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med. 2010;170(9):765–71. doi:10.1001/archinternmed.2010.94.CrossRefPubMedPubMedCentral

26.

Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ Can Med Assoc J. 2008;179(4):319–26. doi:10.1503/cmaj.071330.CrossRef

27.

Dial MS. Proton pump inhibitor use and enteric infections. Am J Gastroenterol. 2009;104(Suppl 2):S10–6. doi:10.1038/ajg.2009.46.CrossRefPubMed

28.

Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149(6):391–8.CrossRefPubMed

29.

Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ Can Med Assoc J. 2011;183(3):310–9. doi:10.1503/cmaj.092129.CrossRef

30.

Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201–11. doi:10.1007/s40264-014-0144-0.CrossRefPubMedPubMedCentral

31.

Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937–44. doi:10.1001/jama.2009.261.CrossRefPubMed

32.

Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–17. doi:10.1056/NEJMoa1007964.CrossRefPubMed

33.

Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ Can Med Assoc J. 2009;180(7):713–8. doi:10.1503/cmaj.082001.CrossRef

34.

Information for healthcare professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). 2009. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm. Accessed 21 July 2015.

35.

Charlot M, Ahlehoff O, Norgaard ML, Jorgensen CH, Sorensen R, Abildstrom SZ, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010;153(6):378–86. doi:10.7326/0003-4819-153-6-201009210-00005.CrossRefPubMed

36.

Schmidt M, Johansen MB, Robertson DJ, Maeng M, Kaltoft A, Jensen LO, et al. Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. Aliment Pharmacol Ther. 2012;35(1):165–74. doi:10.1111/j.1365-2036.2011.04890.x.CrossRefPubMed

37.

Valkhoff VE, t Jong GW, Van Soest EM, Kuipers EJ, Sturkenboom MC. Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. Aliment Pharmacol Ther. 2011;33(1):77–88. doi:10.1111/j.1365-2036.2010.04485.x.CrossRefPubMed

38.

Dunn SP, Macaulay TE, Brennan DM, Campbell CL, Charnigo RJ, Smyth SS et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation. 2008;118(S_815).

39.

Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965–74. doi:10.1016/j.ijcard.2012.03.085.CrossRefPubMed

40.

Melloni C, Washam JB, Jones WS, Halim SA, Hasselblad V, Mayer SB, et al. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review. Circ Cardiovasc Qual Outcomes. 2015;8(1):47–55. doi:10.1161/circoutcomes.114.001177.CrossRefPubMed

41.

Cardoso RN, Benjo AM, DiNicolantonio JJ, Garcia DC, Macedo FY, El-Hayek G, et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart. 2015;2(1):e000248. doi:10.1136/openhrt-2015-000248.CrossRefPubMedPubMedCentral

42.

Blackburn DF, Lamb DA, McLeod MM, Eurich DT. Increased use of acid-suppressing drugs before the occurrence of ischemic events: a potential source of confounding in recent observational studies. Pharmacotherapy. 2010;30(10):985–93. doi:10.1592/phco.30.10.985.CrossRefPubMed

43.

Turkiewicz A, Vicente RP, Ohlsson H, Tyden P, Merlo J. Revising the link between proton-pump inhibitors and risk of acute myocardial infarction—a case-crossover analysis. Eur J Clin Pharmacol. 2015;71(1):125–9. doi:10.1007/s00228-014-1779-6.CrossRefPubMed

44.

Juurlink DN, Dormuth CR, Huang A, Hellings C, Paterson JM, Raymond C, et al. Proton pump inhibitors and the risk of adverse cardiac events. PLoS One. 2013;8(12):e84890. doi:10.1371/journal.pone.0084890.CrossRefPubMedPubMedCentral

45.

Shih CJ, Chen YT, Ou SM, Li SY, Chen TJ, Wang SJ. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int J Cardiol. 2014;177(1):292–7. doi:10.1016/j.ijcard.2014.09.036.CrossRefPubMed

46.

Shah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer SV, Marcus J, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10(6):e0124653. doi:10.1371/journal.pone.0124653.CrossRefPubMedPubMedCentral

47.

Charlot M, Grove EL, Hansen PR, Olesen JB, Ahlehoff O, Selmer C, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ (Clinical research ed). 2011;342:d2690. doi:10.1136/bmj.d2690.CrossRefPubMedCentral

48.

Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012;125(8):978–86. doi:10.1161/circulationaha.111.032912.CrossRefPubMed

49.

Cooke JP. The pivotal role of nitric oxide for vascular health. Can J Cardiol. 2004;20(Suppl B):7b–15b.

50.

Tsao PS, Wang B, Buitrago R, Shyy JY, Cooke JP. Nitric oxide regulates monocyte chemotactic protein-1. Circulation. 1997;96(3):934–40.CrossRefPubMed

51.

Sukhovershin RA, Yepuri G, Ghebremariam YT. Endothelium-derived nitric oxide as an antiatherogenic mechanism: implications for therapy. Methodist DeBakey Cardiovasc J. 2015;11(3):166–71. doi:10.14797/mdcj-11-3-166.CrossRefPubMedPubMedCentral

52.

Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of l-arginine in the hypercholesterolemic rabbit. J Clin Investig. 1992;90(3):1168–72. doi:10.1172/jci115937.CrossRefPubMedPubMedCentral

53.

Candipan RC, Wang BY, Buitrago R, Tsao PS, Cooke JP. Regression or progression. Dependency on vascular nitric oxide. Arterioscler Thromb Vasc Biol. 1996;16(1):44–50.CrossRefPubMed

54.

Niebauer J, Dulak J, Chan JR, Tsao PS, Cooke JP. Gene transfer of nitric oxide synthase: effects on endothelial biology. J Am Coll Cardiol. 1999;34(4):1201–7.CrossRefPubMed

55.

Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98(18):1842–7.CrossRefPubMed

56.

Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke J Cereb Circ. 2006;37(8):2024–9. doi:10.1161/01.str.0000231640.32543.11.CrossRef

57.

Wilson AM, Shin DS, Weatherby C, Harada RK, Ng MK, Nair N, et al. Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease. Vasc Med (London, England). 2010;15(4):267–74. doi:10.1177/1358863x10364552.CrossRefPubMedCentral

58.

Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 2000;20(9):2032–7.CrossRefPubMed

59.

Boger RH, Cooke JP, Vallance P. ADMA: an emerging cardiovascular risk factor. Vasc Med (London, England). 2005;10(Suppl 1):S1–2.

60.

Cooke JP, Ghebremariam YT. DDAH says NO to ADMA. Arterioscler Thromb Vasc Biol. 2011;31(7):1462–4. doi:10.1161/atvbaha.111.228833.CrossRefPubMedPubMedCentral

61.

Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, Wang BY, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation. 2003;108(24):3042–7. doi:10.1161/01.cir.0000101924.04515.2e.CrossRefPubMed

62.

Ghebremariam YT, Erlanson DA, Yamada K, Cooke JP. Development of a dimethylarginine dimethylaminohydrolase (DDAH) assay for high-throughput chemical screening. J Biomol Screen. 2012;17(5):651–61. doi:10.1177/1087057112441521.CrossRefPubMedPubMedCentral

63.

Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128(8):845–53. doi:10.1161/circulationaha.113.003602.CrossRefPubMed

64.

Weitzberg E, Hezel M, Lundberg JO. Nitrate–nitrite–nitric oxide pathway: implications for anesthesiology and intensive care. Anesthesiology. 2010;113(6):1460–75. doi:10.1097/ALN.0b013e3181fcf3cc.CrossRefPubMed

65.

Lundberg JO, Weitzberg E, Lundberg JM, Alving K. Intragastric nitric oxide production in humans: measurements in expelled air. Gut. 1994;35(11):1543–6.CrossRefPubMedPubMedCentral

66.

Montenegro MF, Lundberg JO. Letter by Montenegro and Lundberg regarding article, “Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine”. Circulation. 2014;129(13):e426. doi:10.1161/circulationaha.113.005585.CrossRefPubMed

67.

Pinheiro LC, Amaral JH, Tanus-Santos JE. Letter by Pinheiro et al regarding article, “Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine”. Circulation. 2014;129(13):e427. doi:10.1161/circulationaha.113.005307.CrossRefPubMed

68.

Pinheiro LC, Montenegro MF, Amaral JH, Ferreira GC, Oliveira AM, Tanus-Santos JE. Increase in gastric pH reduces hypotensive effect of oral sodium nitrite in rats. Free Radic Biol Med. 2012;53(4):701–9. doi:10.1016/j.freeradbiomed.2012.06.001.CrossRefPubMed

69.

Amaral JH, Montenegro MF, Pinheiro LC, Ferreira GC, Barroso RP, Costa-Filho AJ, et al. TEMPOL enhances the antihypertensive effects of sodium nitrite by mechanisms facilitating nitrite-derived gastric nitric oxide formation. Free Radic Biol Med. 2013;65:446–55. doi:10.1016/j.freeradbiomed.2013.07.032.CrossRefPubMed

70.

Pinheiro LC, Amaral JH, Ferreira GC, Portella RL, Ceron CS, Montenegro MF, et al. Gastric S-nitrosothiol formation drives the antihypertensive effects of oral sodium nitrite and nitrate in a rat model of renovascular hypertension. Free Radic Biol Med. 2015;87:252–62. doi:10.1016/j.freeradbiomed.2015.06.038.CrossRefPubMed

71.

Lundberg JO, Weitzberg E, Gladwin MT. The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov. 2008;7(2):156–67. doi:10.1038/nrd2466.CrossRefPubMed

72.

Carlstrom M, Persson AE, Larsson E, Hezel M, Scheffer PG, Teerlink T, et al. Dietary nitrate attenuates oxidative stress, prevents cardiac and renal injuries, and reduces blood pressure in salt-induced hypertension. Cardiovasc Res. 2011;89(3):574–85. doi:10.1093/cvr/cvq366.CrossRefPubMed

73.

McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol. 2009;104(Suppl 2):S5–9. doi:10.1038/ajg.2009.45.CrossRefPubMed

74.

Kyrtopoulos SA. Ascorbic acid and the formation of N-nitroso compounds: possible role of ascorbic acid in cancer prevention. Am J Clin Nutr. 1987;45(5 Suppl):1344–50.PubMed

75.

Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation. 2003;108(8):933–8. doi:10.1161/01.cir.0000085067.55901.89.CrossRefPubMed

76.

Dayal S, Lentz SR. ADMA and hyperhomocysteinemia. Vasc Med (London, England). 2005;10(Suppl 1):S27–33.

77.

Perazella MA. Proton pump inhibitors and hypomagnesemia: a rare but serious complication. Kidney Int. 2013;83(4):553–6. doi:10.1038/ki.2012.462.CrossRefPubMed

78.

Toh JW, Ong E, Wilson R. Hypomagnesaemia associated with long-term use of proton pump inhibitors. Gastroenterol Rep. 2014;. doi:10.1093/gastro/gou054.

79.

Leto L, Aspromonte N, Feola M. Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review. Heart Fail Rev. 2014;19(2):237–46. doi:10.1007/s10741-012-9354-7.CrossRefPubMed

80.

Wargo KA, Banta WM. A comprehensive review of the loop diuretics: should furosemide be first line? Ann Pharmacotherapy. 2009;43(11):1836–47. doi:10.1345/aph.1M177.CrossRef

81.

Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012;36(5):405–13. doi:10.1111/j.1365-2036.2012.05201.x.CrossRefPubMed

82.

Ghebremariam YT, Cooke JP, Khan F, Thakker RN, Chang P, Shah NH, et al. Proton pump inhibitors and vascular function: a prospective cross-over pilot study. Vasc Med (London, England). 2015. doi:10.1177/1358863x14568444.

83.

Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2004;5(2):181–202. doi:10.1517/phgs.5.2.181.27483.CrossRefPubMed

84.

Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther. 2001;15(12):1929–37.CrossRefPubMed

85.

Depta JP, Lenzini PA, Lanfear DE, Wang TY, Spertus JA, Bach RG, et al. Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction. Pharmacogenomics J. 2015;15(1):20–5. doi:10.1038/tpj.2014.28.CrossRefPubMedPubMedCentral

86.

Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol. 2007;293(6):H3227–45. doi:10.1152/ajpheart.00998.2007.CrossRefPubMed

87.

Valkonen VP, Tuomainen TP, Laaksonen R. DDAH gene and cardiovascular risk. Vasc Med (London, England). 2005;10(Suppl 1):S45–8.

88.

Ryan R, Thornton J, Duggan E, McGovern E, O’Dwyer MJ, Ryan AW, et al. Gene polymorphism and requirement for vasopressor infusion after cardiac surgery. Ann Thorac Surg. 2006;82(3):895–901. doi:10.1016/j.athoracsur.2006.04.029.CrossRefPubMed

Title: How May Proton Pump Inhibitors Impair Cardiovascular Health?
Authors: Roman A. Sukhovershin
John P. Cooke
Publication date: 01-06-2016
Publisher: Springer International Publishing
Published in: American Journal of Cardiovascular Drugs / Issue 3/2016
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI: https://doi.org/10.1007/s40256-016-0160-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

How May Proton Pump Inhibitors Impair Cardiovascular Health?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

Efficacy of Short-Term Statin Treatment for the Prevention of Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Angiography/Percutaneous Coronary Intervention: A Meta-Analysis of 21 Randomized Controlled Trials

Anti-Anginal and Metabolic Effects of Carvedilol and Atenolol in Patients with Stable Angina Pectoris: A Prospective, Randomized, Parallel, Open-Label Study

Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review

Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?

Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options